IMNN•benzinga•
IMUNON Announces Six-Month Data From Phase 1 Proof-Of-Concept Trial Of Its IMNN-101 NA Vaccine Platform; Says Its PlaCCine Platform 'demonstrates better durability and other advantages compared to mRNA vaccines'
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 15, 2025 by benzinga